Linotype Atomatic™ font family
Designed by Johannes Plass in 1997
Linotype Atomatic™ is part of the TakeType Library, selected from the contestants of Linotype’s International Type Design Contests of 1994 and 1997. German artist Johannes Plass designed his font in one strongly-crafted weight. Linotype Atomatic seems to mirror the fast pace and technology of modern times. The slight lean to the right gives an impression of speed and movement. Linotype Atomatic is intended exclusively for headlines in larger point sizes.
More related documents:
be installed on a computer for
use with applications.
Licensed per computer.
@font-face rule. They are licensed
for a set number of page views with
no time limitation.
embedded in an eBook, eMagazine or
eNewspaper. Fonts are licensed per title.
a server and e.g. used by automated
processes to create items.
A license is per server core CPU per year.
on which the font will be installed.
that you can use over time. We’ll let
you know when you’re running low.
installations you want to license.
Some mobile app fonts allow an
unlimited number of installations.
you intend to embed the font in. Each license
is valid for one title for the life of that title.
CPUs of the servers on which
the font will be installed.
A license has a term of 1 year.
language support of the font.
the font: W1G (98 languages),
COM (56 languages),
PRO (33 languages) or
STD (21 languages).
available in. These differ in contained
characters and file size. You get all
available versions with your license.
Typecast is a web-based tool to create visual
and semantic designs. Check for readability,
rendering and beauty then share a working
prototype of your design.
Tip: Add fonts to your Favorites, then test your custom selection in Typecast!
Std / OT CFF
supports at least
Download a free trial
Use this font in your own documents with a free 5 minute trial through SkyFonts. Trials are for evaluation purposes only. Learn more.
This font is currently not available.
You already tried this font within the last 24 hours or you may have exceeded your daily allowance of trials. Learn more.